The Brigham and Women's Hospital, Inc.

Beth Israel Deaconess Medical Center, Inc.

Mark Feinberg

Santosh Ambadas Khedkar

Xinghui Sun

Akm Khyrul Wara

Basak Icli

The invention relates to compositions and methods for inhibiting Krüppel-like Factor 10 (KLF10) for modulation of T regulatory cells and cancer immunotherapy.

Use of small molecule inhibitors to KLF10 for modulation of T regulatory cells and cancer immunotherapy

The invention relates to compositions and methods for inhibiting Kr&#xfc;ppel-like Factor 10 (KLF10) for modulation of T regulatory cells and cancer immunotherapy.

Methods for enhancing wound healing, e.g., in diabetic subjects, by administering an antagonist of miR-26a, e.g., an inhibitory nucleic acid that targets miR-26a.

Enhancing dermal wound healing by downregulating microRNA-26a

The present invention features methods and compositions for the non-invasive detection of organ rejection using a microRNA score.

Detection of organ rejection

Provided are methods of treating or delaying the onset of a vascular inflammatory disease (e.g., acute lung injury) in a subject including administering to the subject a therapeutically effective amount of a nucleic acid containing all or a part of the sequence of mature miR-181b (SEQ ID NO: 1). Also provided are methods of decreasing nuclear factor-&#x3ba;&#x3b2; (NF-&#x3ba;&#x3b2;) signaling in an endothelial cell including administering to the subject a nucleic acid containing all or a part of the sequence of mature miR-181b (SEQ ID NO: 1).

Methods of treating vascular inflammatory disorders

The use of Kruppel-like Factor (KLF10) as a diagnostic and prognostic tool for peripheral artery disease and other disease conditions associated with reduced angiogenesis or endothelial progenitor cell dysfunction such as diabetes and stent thrombosis.

Kruppel-like factor 10 (KLF10) as a biomarker of endothelial progenitor cell dysfunction

Methods for promoting angiogenesis, and for diagnosing the presence or risk of developing disorders associated with impaired angiogenesis or blood flow to a tissue in the body, using microRNA-26a (miR-26a).

Methods of using microRNA-26a to promote angiogenesis

Provided are methods of treating or delaying the onset of a vascular inflammatory disease (e.g., acute lung injury) in a subject including administering to the subject a therapeutically effective amount of a nucleic acid containing all or a part of the sequence of mature miR-181b (SEQ ID NO: 1). Also provided are methods of decreasing nuclear factor-R? (NF-R?) signaling in an endothelial cell including administering to the subject a nucleic acid containing all or a part of the sequence of mature miR-181b (SEQ ID NO: 1).

The present invention provides methods and compositions for treating chronic inflammatory disease in a subject and associated pharmaceutical compositions, medical devices and systems.

Growing community of inventors

Newton, MA, United States of America

Mark Feinberg